Background: The use of analyses for methylmalonic acid (MMA) and total homocysteine (HCY) in plasma has become widespread. Realizing the need for external quality assessment for these measurements, we started a program in 1997. The results for 1998 are reviewed in this report. Methods: Fourteen laboratories participated with 15 sets of results for MMA, and 28 laboratories participated with 34 sets of results for HCY. Results for four identical samples, made up from the same unmodified serum (MMA) or EDTA-plasma (HCY) pool, sent out under different identifications, were used for assessing the imprecision. Samples made up from the same pools supplemented with MMA or L-HCY to three concentrations were used for assessing the recovery. By using literature data for the biological variation, quality goals for both analytes were calculated. Results: The overall within-laboratory CV was 12% for MMA and 7.5% for HCY. Gas chromatography-mass spectrometric HCY results had lower imprecision than the HPLC or immunoassay results. For MMA, no significant between-laboratory component of variance was found. Only results for HCY obtained with HPLC methods showed significant between-laboratory variance. Conclusions: Eight of the 15 participants achieved the minimum imprecision goal for MMA vs 9 of the 34 participants for HCY. The minimum quality goals for bias as approximated by the recovery were achieved by 13 participants for MMA and 26 for HCY.
The analysis of methylmalonic acid (MMA) 1 in serum and plasma is a valuable tool in the diagnosis of cobalamin deficiency (1, 2 ) , and with the advent of practicable analytical methods during the last decade (3 ) , MMA analysis has become more widespread. With this increased usage of MMA, the incidence of cobalamin deficiency is higher than assumed previously, in particular among the elderly (4 ) .
In addition to being an extremely useful test in establishing the presence of folate deficiency and in differentiating cobalamin and folate deficiencies (1, 2 ) , the analysis of total homocysteine (HCY) in plasma has achieved a pivotal role in the investigation of hyperhomocysteinemia as a possible independent risk factor for occlusive vascular disease (5, 6 ) . The demand for HCY analyses has lead to the development of more practicable and robust methods. With the introduction of new HPLC kits, and in particular with the new immunoassays (7, 8 ) , many laboratories are now offering analysis of HCY in plasma as part of their service.
The increasing use of these analytes emphasizes the need for an external quality assessment program, and following a pilot study in 1996 (9 ) , we started a program in 1997 in collaboration with The Danish Institute for External Quality Assurance for Hospital Laboratories (DEKS). The results for 1998 are reviewed in the present report.
samples All sample material originated from the blood banking services of the Department of Clinical Immunology, Aarhus University Hospital, where it was screened for human T-cell leukemia/lymphoma virus, hepatitis virus, and HIV.
For the MMA samples, the same serum pools were used for all 12 samples, either unmodified or supplemented with MMA (Cat. no. 67 750; Fluka AG). Supplemented samples were made up by adding MMA in a stock solution of 250 mol/L to the serum pool, corresponding to an increase in concentrations of 0.05, 0.20, and 1.00 mol/L, respectively. One set of samples was prepared by diluting the serum pool 1:2 with an albumin solution [65 g/L human serum albumin (Kabi) in 9 g/L NaCl].
For the HCY samples, a pool of plasma was obtained from blood containing 3.8 mmol/L EDTA as an anticoagulant (EDTA, disodium salt; Sigma Cat. no. E5134; Sigma-Aldrich) and used for the 12 samples, unmodified or supplemented with l-homocystine (Sigma Cat. no. H6010; Sigma-Aldrich). Supplemented samples were made up by adding l-homocystine in a stock solution of 10 mmol/L to the plasma pool, corresponding to an increase in concentrations of 5, 20, and 75 mol/L, respectively. One set of samples was prepared by diluting the plasma pool 1:2 with the same 65 g/L albumin solution used for the MMA samples. The samples were prepared at the start of the year and kept at Ϫ20°C until shipment.
protocol
The unmodified samples were sent out in four rounds during the year. The diluted and supplemented samples were distributed twice. All samples were numbered consecutively to disguise the identity. Table 1 lists the samples sent out in each round.
calculations
The imprecision of the laboratories was calculated using the results from the unmodified samples, and the alllaboratory mean was taken to be the best estimate of the The samples, MMA 11 and HCY 11, were made up from an unmodified serum or plasma pool, respectively, sent out under different identifications in four of the six rounds. In the graphic presentation, the results are presented in increasing order, and the arrow points to the result of the actual laboratory. Serum supplemented with 1.00 mol/L Plasma supplemented with 75 mol/L target concentration of the unmodified sample. The recovery for each of the supplemented samples was calculated for each laboratory by subtracting the target concentration of the unmodified sample from the mean of all the duplicate determinations and dividing by the added concentration of MMA or HCY, respectively. The mean recovery for each laboratory was measured by calculating the least-squares slope between the expected increments of MMA or HCY and the actual results for the respective samples. Unweighted linear regression was used to minimize the influence of the result for the concentration of the unmodified sample obtained by the individual laboratory.
For HCY, an attempt was made to group the results into three groups according to the type of analytical method used: all HPLC methods (HPLC); gas chromatography-mass spectrometry and liquid chromatographymass spectrometry (MS), and enzyme immunoassays and fluorescence polarization immunoassays (IMMUN).
statistical methods
Results for the individual samples are given as mean Ϯ SD and/or CVs and ranges. Differences between means were tested using the Wilcoxon test, and between variances were tested using F-tests. Within-and betweenlaboratory variations were calculated using analysis of variance and stated as SDs and CVs. Unless otherwise stated, a level of significance of 0.05 was assumed. Outliers were detected using Dixon's test with a level of significance of 0.01.
Results mma
Of the 16 laboratories registered for the program, 14 returned results, with 1 laboratory using two different methods. In total, a maximum of 15 sets of results was returned after each of the six rounds. The results are summarized in Table 2 .
The distribution of the results for the unmodified sample and the imprecision of the individual laboratories are shown in Fig. 2 . The recovery of the added MMA was 98.7% on average, with a range of 89 -108%. The differences between the reported and expected results are shown in Fig. 3 . In addition, the histogram shows the distribution of the recoveries of the individual laboratories.
For the set of samples diluted 1:2 with the albumin solution, the imprecision was 22%, significantly (P Ͻ0.01) higher than for the unmodified sample, and the ratio between the mean result for the diluted sample and the unmodified sample was 0.56 (range, 0.44 -0.77), significantly higher than the expected ratio of 0.50 (Wilcoxon test, 0.05 Ͼ P Ͼ 0.02). Five participants found ratios lower than 0.50, and 10 participants found ratios higher than 0.50. 
total hcy
Of the 28 laboratories registered for the program, 3 returned results for more than one method, and in total, a maximum of 34 sets of results was returned in each of the six rounds. Twelve sets of results were in the HPLC method group, 6 in the MS method group, and 16 in the IMMUN method group. The results are summarized in Table 3 . The distribution of the results for the unmodified sample is shown in Fig. 4 , together with the CVs of the individual laboratories. The recovery of the added HCY was 96.4% on average, with a range of 76.2-116.5%. The differences between the reported and expected results are shown in Fig. 5 . In addition, the histogram shows the distribution of the recoveries of the individual laboratories.
For the set of samples diluted 1:2 with the albumin solution, the mean concentration was 12.0 mol/L, corresponding to a concentration of 14 mol/L in the albumin solution, or a content of 0.2 mol/L HCY per gram of albumin. The within laboratory imprecision was 8.4%, significantly (P Ͻ0.05) higher than for the unsupplemented sample. This matrix effect was seen in all three method groups.
The precision data from the four determinations of the unmodified sample are presented according to method group in Table 3 . The HPLC group is the only group with significant variation among laboratories. The within-laboratory variance of the MS method group was significantly (P Ͻ0.05) lower than those of the other two groups.
The results for the sample supplemented with 75 mol/L showed the largest relative variation. Most results from the IMMUN methods had to be diluted for the high concentration, and to check whether this dilution was the origin of the high variation, the results were analyzed according to method group. The CVs were not different for the HPLC and the IMMUN methods (11% for both methods) but significantly (P Ͻ0.05) lower for the MS methods (6.2%).
Discussion
For the determination of the precision of the analyses of MMA and HCY, unmodified samples made up from serum and EDTA-plasma pools, respectively, were distributed. The consequence of this approach is that the concentrations were limited to within the reference range if material was collected from healthy blood donors. Top, the mean recovery for all participants was 99%. The differences between the reported and expected results are shown with lines indicating the limits for bias consistent with desirable performance (Ϯ6%) and minimum performance (Ϯ9%). The error bars represent Ϯ2 SD. Bottom, the mean recovery for each laboratory, calculated as the least squares slope between the expected increments of MMA and the actual results for the respective samples are shown. Recoveries within the limits for bias consistent with desirable performance (Ϯ6%) are represented with white columns, and recoveries within the limits for minimum performance (Ϯ9%) are represented with gray columns. The black columns represent recoveries outside the limits for minimum performance. Although a measure of imprecision can be derived from the duplicate determinations of the supplemented samples, these results must be interpreted with caution for HCY. Serum with MMA added will be close to the genuine samples, but plasma supplemented with l-homocystine will have a distribution of HCY quite different from physiological samples, where Ͼ60% of the HCY is protein bound (10 ) , because the disulfide is stable and will not react with the proteins of the matrix to any significant degree. The ideal material would consist of mixtures of plasma with low and high concentrations of HCY acquired from a limited number of volunteers. Accepting large portions of blood from individuals with sufficiently high concentrations of HCY would, however, be considered unethical. For now, the supplemented samples for HCY must be accepted as the best solution.
Diluting the sample material with the albumin solution did not provide information on the linearity of the methods because the albumin, as expected, contained HCY bound with disulfide links and may also have contained trace amounts of MMA, because the majority of participants found a ratio of concentrations of the unmodified and the diluted sample of more than the expected 0.50. However, our intention was to test whether the methods demonstrated a matrix effect. For both analytes, a modest but significant dependence of the sample matrix could be detected because the variation was higher for the albumin-diluted samples.
In assessing the performance of the analyses, we assumed that the laboratories used the same number of replicates as used for clinical samples. This may not be the case, because some laboratories could have used more replicates for these quality assurance samples. Therefore, the estimate reported here may be overly optimistic.
If the between-laboratory variation could be explained by differences in calibration, there should have been a correlation between the recovery and the mean value of the unmodified samples. This was not found to be the case for either MMA or HCY.
The aim of a quality assessment scheme is to evaluate both the imprecision and the bias of the analytical methods of the participants. The accepted approach when quantifying the bias depends on reference methods or reference preparations. However, neither of these is available for MMA or HCY. Instead, recovery was assessed using supplementation of the unmodified samples, determined four times by each participant. When using recovery as an estimation of bias, the calibrations of the methods are taken into account, but the differences in specificity of the analytical methods are disregarded. When using recovery as an estimate of bias, the bias will always be underestimated. In this study, where unmodified material from healthy blood donors was used, the difference between bias and recovery would have been quite small, because the differences of the results for the unmodified samples were small compared with the amounts used when supplementing the samples. However, the apparent matrix dependence of the methods, as evidenced by the larger variation of the samples diluted Results (n ϭ 132) for the unmodified plasma pool were submitted from 28 laboratories, 3 submitting results from more than one method. One result, 17.5 mol/L, was classified as an outlier (Dixon's test, P Ͻ0.01) and excluded, leaving 131 results for the statistical analysis. CVs within the limits for desirable performance (Ͻ4%) are represented with white columns, and CVs within the limits for minimum performance (6%) are represented with gray columns. The black columns represent CVs outside the limits for minimum performance. with an albumin solution, may well have been caused by differences in the specificity of the methods. Sample material with a high content of MMA or HCY, e.g., from subjects with inborn errors of metabolism, may well exhibit larger differences in specificity and bias. Lacking better alternatives, we used recovery as an estimate for the bias of the results in this study. When reporting data on analytical performance, quality goals for the analyses are needed. According to Fraser et al. (11 ) , desirable performance is defined as an analytical imprecision less than 0.5 ϫ CV Within subject and mini-mum performance as 0.75 ϫ CV Within subject . For the analytical bias, desirable performance is defined as a bias less than 0.25 ϫ CV Biological , and minimum performance is defined as a bias less than 0.375 ϫ CV Biological . For HCY, CV Within subject and CV Between subject have been the subject of several investigations (12) (13) (14) (15) , and the CV Biological is calculated as (CV Within subject 2 ϩ CV Between subject 2 ) 1/2 and for MMA as one-quarter of the range of the reference interval corrected for the analytical variation, because there is a well-documented reference interval, not dependent on age and gender (16 ) .
For MMA, the CV Within subject was 13% (17 ); thus, desirable and minimum performance for imprecision by the Fraser et al. (11 ) criteria will be 7% and 10%, respectively, achieved by 4 and 8 participants of the 15. Assuming a reference interval of 0.08 -0.28 mol/L (16 ) and correcting for the analytical variation of 0.02 mol/L found in this study, the CV Biological was 25%, and desirable and minimum performance for bias were 6% and 9%, respectively, achieved by 11 and 13 participants of the 15. Generally, the bias seemed to be within acceptable limits for the majority of laboratories, but the precision needed improvement. That the bias was generally within acceptable limits was supported by the fact that we found no significant component of variance between the laboratories for the whole range of concentrations used, signifying that reference intervals and limits of decision meaningfully can be compared and discussed among the laboratories.
For HCY, there are inconsistent reports of the CV Within subject (12) (13) (14) (15) , but the values of 7-9% found in Refs. (12) (13) (14) are in agreement with our experience. Thus, desirable and minimum performance would be 4% and 6%, respectively, achieved by 1 and 9 participants of the 34. The CV Between subject was between 25% and 33% in Refs. (12) (13) (14) ; assuming a mean CV Between subject of 30%, the desirable performance for bias would be 8%, and the minimum performance for bias would be 11%, achieved by 22 and 26 participants of the 34, respectively. For the method groups, only the MS group had a within-laboratory imprecision lower than the cutoff for minimum performance, and there was no significant between-laboratory variation for the IMMUN or the MS group. This was not surprising, because the HPLC methods showed much more disparate performance than the other methods. In fact, the method with the lowest imprecision belonged to the HPLC group. That the MS methods on average had the lowest within-laboratory variation may have been related to the fact that only laboratories with a high level of technical competence chose the MS methods, rather than because of a characteristic of the methods themselves.
In conclusion, there is still room for improvement of the imprecision for both analyses. The present findings also suggest that there is a need for reduction of the bias for HCY. With the recent introduction of the HPLC kits and L-Homocystine was added to the pool of EDTA-plasma corresponding to an increase of HCY of three different concentrations, 5, 20, and 75 mol/L. The mean recovery for all participants as calculated from the slope of the regression line was 96%. Top, the differences between the reported and expected results are shown with lines indicating the limits for bias consistent with desirable performance (Ϯ8%) and minimum performance (Ϯ11%). The intercept of the regression line is 9.83 mol/L, in agreement the mean result of 10.0 mol/L for the unmodified plasma samples. Bottom, mean recoveries for each laboratory, within the limits for bias consistent with desirable performance (Ϯ8%), are represented with white columns, and within the limits for minimum performance (Ϯ11%) are represented with gray columns. The black columns represent recoveries outside the limits for minimum performance . immunoassays for HCY, external quality assessment is more essential than ever. In agreement with the finding that most laboratories exhibited recoveries within the suggested limits for bias, no significant variation between laboratories was found for MMA, making meaningful comparisons and discussions of decision levels and reference intervals possible.
